Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Abstract Bruton’s tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B‐cell receptor and Fc‐receptors. Tolebrutinib (PRN2246, SAR442168) is a potent BTK inhibitor that covalently binds the kinase, resulti...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Timothy D. Owens, Patrick F. Smith, Andrew Redfern, Yan Xing, Jin Shu, Dane E. Karr, Sonja Hartmann, Michelle R. Francesco, Claire L. Langrish, Philip A. Nunn, Steven G. Gourlay
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-02-01
coleção:	Clinical and Translational Science
Acesso em linha:	https://doi.org/10.1111/cts.13162
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!